ADAGENE INC-ADR Share Price Today: Live Updates & Key Insights

ADAGENE INC-ADR share price today is $3.17, up -5.04%. The stock opened at $3.592 against the previous close of $3.37, with an intraday high of $3.592 and low of $3.17.

ADAGENE INC-ADR Share Price Chart

ADAGENE INC-ADR

us-stock
To Invest in {{usstockname}}
us-stock

ADAGENE INC-ADR Share Price Performance

$3.17 -0.0504(-5.04%) ADAG at 27 Jul 2026 01:50 PM Biotechnology
Lowest Today 3.17
Highest Today 3.592
Today’s Open 3.592
Prev. Close 3.37
52 Week High 4.85
52 Week Low 1.30
Day’s Range: Low 3.17 High 3.592
52-Week Range: Low 1.30 High 4.85
1 day return -
1 Week return -14.09
1 month return -24.52
3 month return -10.95
6 month return +28.86
1 year return +24.8
3 year return +134.81
5 year return -81.97
10 year return -

ADAGENE INC-ADR Institutional Holdings

HSG Holding Ltd 2.03

Exome Asset Management LLC 1.12

Ameriprise Financial Inc 0.92

Mill Creek Capital Advisors LLC 0.30

Fullgoal Glb Healt Life Alloc(QDII)USD 0.16

Morgan Stanley - Brokerage Accounts 0.10

Amvescap Plc. 0.07

Invesco Golden Dragon China ETF 0.07

SmartHarvest Portfolios, LLC 0.06

Kamunting Street Cap Management, L.p. 0.06

Persistent Asset Partners Limited 0.05

Dauntless Investment Group, LLC 0.05

Renaissance Technologies Corp 0.05

Jane Street Group LLC 0.05

Alyeska Investment Group, L.P. 0.03

Royal Bank of Canada 0.03

Nomura Holdings Inc 0.02

Quadrature Capital Limited 0.02

Fidelity Nasdaq Composite Index 0.02

Geode Capital Management, LLC 0.02

UBS Group AG 0.01

BNP Paribas Arbitrage, SA 0.01

EverSource Wealth Advisors, LLC 0.00

ADAGENE INC-ADR Market Status

Strong Buy: 0

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

ADAGENE INC-ADR Fundamentals

Market Cap 222.66 M

PB Ratio 6.6915

PE Ratio 0.0

Enterprise Value 168.28 M

Total Assets 78.26 M

Volume 127526

ADAGENE INC-ADR Company Financials

Annual Revenue FY23:18111491 18.1M, FY22:9292724 9.3M, FY21:10175258 10.2M, FY20:480000 0.5M, FY19:480000 0.5M

Annual Profit FY23:18111491 18.1M, FY22:9292724 9.3M, FY21:10175258 10.2M, FY20:480000 0.5M, FY19:480000 0.5M

Annual Net worth FY23:-18946370 -18.9M, FY22:-79971847 -80.0M, FY21:-73177935 -73.2M, FY20:-16435472 -16.4M, FY19:-17293880 -17.3M

Quarterly Revenue Q1/2026:7692937 7.7M, Q2/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M, Q1/2024:null 0.0M

Quarterly Profit Q1/2026:7410617 7.4M, Q2/2025:-300326 -0.3M, Q3/2024:null 0.0M, Q2/2024:null 0.0M, Q1/2024:null 0.0M

Quarterly Net worth Q1/2026:-4144043 -4.1M, Q2/2025:-13510369 -13.5M, Q3/2024:-8505858 -8.5M, Q2/2024:-8505858 -8.5M, Q1/2024:-8505858 -8.5M

About ADAGENE INC-ADR & investment objective

Company Information Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Organisation Biotechnology

Employees 128

Industry Biotechnology

CEO Dr. Peter P. Luo Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

ADAGENE INC-ADR FAQs

What is the share price of ADAGENE INC-ADR today?

The current share price of ADAGENE INC-ADR is $3.17.

Can I buy ADAGENE INC-ADR shares in India?

Yes, Indian investors can buy ADAGENE INC-ADR shares by opening an international trading and demat account with Motilal Oswal.

How to buy ADAGENE INC-ADR shares in India?

You can easily invest in ADAGENE INC-ADR shares from India by:

Can I buy fractional shares of ADAGENE INC-ADR?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of ADAGENE INC-ADR?

ADAGENE INC-ADR has a market cap of $222.66 M.

In which sector does ADAGENE INC-ADR belong?

ADAGENE INC-ADR operates in the Biotechnology sector.

What documents are required to invest in ADAGENE INC-ADR stocks?

To invest, you typically need:

What is the PE and PB ratio of ADAGENE INC-ADR?

The PE ratio of ADAGENE INC-ADR is N/A and the PB ratio is 6.69.